Nuvation Bio Inc Ordinary Shares - Class A NUVB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NUVB is a good fit for your portfolio.
News
-
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
-
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
-
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
-
Thinking about buying stock in BigBear.ai, Bitfarms, Paysign, Nuvation Bio, or One Group Hospitality?
-
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
-
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
-
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $3.41
- Day Range
- $3.28–3.47
- 52-Week Range
- $0.95–4.16
- Bid/Ask
- $3.22 / $3.37
- Market Cap
- $823.93 Mil
- Volume/Avg
- 819,080 / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 51
- Website
- https://www.nuvationbio.com
Comparables
Valuation
|
Metric
|
NUVB
|
CLDX
|
MRSN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.26 | 3.00 | 11.28 |
Price/Sales | — | 323.22 | 8.06 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NUVB
|
CLDX
|
MRSN
|
|---|---|---|---|
Quick Ratio | 38.15 | 31.44 | 3.43 |
Current Ratio | 38.58 | 31.77 | 3.51 |
Interest Coverage | — | — | −34.91 |
Quick Ratio
NUVB
CLDX
MRSN
Profitability
|
Metric
|
NUVB
|
CLDX
|
MRSN
|
|---|---|---|---|
Return on Assets (Normalized) | −7.59% | −23.59% | −41.22% |
Return on Equity (Normalized) | −7.80% | −25.21% | −196.75% |
Return on Invested Capital (Normalized) | −12.07% | −25.04% | −129.55% |
Return on Assets
NUVB
CLDX
MRSN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ndfppfgdk | Tnrrx | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mswwxbgv | Ppvhhq | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Crjdglf | Nkxwfvy | $106.7 Bil | |
MRNA
| Moderna Inc | Stdvyxh | Fymd | $50.9 Bil | |
ARGX
| argenx SE ADR | Snccsrbc | Hgzwl | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Mlhbwkfr | Gyhc | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xqpdwrn | Fxgjkt | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qmgrvgk | Xqfwvq | $14.6 Bil | |
INCY
| Incyte Corp | Qnpndgqb | Jmdlsh | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Drdnpmqby | Spyyyrl | $12.6 Bil |